Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 13/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TEC | P42680 | 1/20 | 0.34 |
| ▸ | TXK | P42681 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | BMX | P51813 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21544159 | 1.00 | TSHR (0.41) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL2033628 | 0.89 | — | — | |
| Dimethylamine SCHEMBL20515125 | 0.83 | TSHR (0.43) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL29942458 | 0.82 | TSHR (0.54) | TSHRMAPTGAASMN1; SMN2 | |
| SCHEMBL29942704 | 0.82 | TSHR (0.54) | TSHRMAPTGAASMN1; SMN2 | |
| SCHEMBL23323365 | 0.82 | TSHR (0.39) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL25976403 | 0.82 | TSHR (0.39) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL22969767 | 0.81 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL24660233 | 0.81 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2JAK3 | |
| SCHEMBL22969921 | 0.81 | TSHR (0.38) | TSHRMAPTGAASMN1; SMN2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790886-B1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-3802535-B1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3807276-A2 | KRAS G12C INHIBITORS ENCOMPASSING A PIPERAZINE RING AND USE THEREOF IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3790886-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200030324-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2019217691-A1 | KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200030324-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4516/4885MAPT 3991/4885GAA 2186/4885 |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4359/4885MAPT 4273/4885GAA 2321/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TSHR 4359/4885MAPT 4273/4885GAA 2321/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4516/4885MAPT 3991/4885GAA 2186/4885 |
| US-20220153741-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | TSHR 4531/4885MAPT 3597/4885GAA 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.